Over 12 months, Climb Bio, Inc. saw more selling than buying from its insiders — purchases of about $780,000 against sales of $2.7 million.
Kolchinsky Peter (Director) made the biggest buy, worth around $465,000.
3 quarters in a row of net selling by insiders. Insiders bought in 2 of the last 7 full quarters. 109 investment managers listed CLYM in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Thomas Stephen Basil | Director | Sell | 100,000 | $13.67 | $1.4M | SEC |
| Jun 30, 2026 | Brennan Aoife | CEO | Sell | 30,902 | $13.17 | $407K | SEC |
| Feb 27, 2026 | Thomas Stephen Basil | Director | Sell | 33,687 | $7.00 | $236K | SEC |
| Feb 27, 2026 | Thomas Stephen Basil | Director | Sell | 16,313 | $7.01 | $114K | SEC |
| Feb 17, 2026 | Thomas Stephen Basil | Director | Sell | 90,000 | $5.23 | $471K | SEC |
| Feb 17, 2026 | Thomas Stephen Basil | Director | Sell | 10,000 | $5.81 | $58K | SEC |
| Jan 7, 2026 | RA Capital Healthcare Fund LP | Director | Buy | 7,111 | $3.50 | $25K | SEC |
| Dec 15, 2025 | Kolchinsky Peter | Director | Buy | 101,462 | $2.86 | $290K | SEC |
| Dec 15, 2025 | Kolchinsky Peter | Director | Buy | 213,099 | $2.18 | $465K | SEC |
| Jul 1, 2025 | Brennan Aoife | CEO | Sell | 20,618 | $1.22 | $25K | SEC |
| Jun 20, 2025 | Pimblett Emily | Executive Officer | Sell | 1,242 | $1.24 | $2K | SEC |
| Mar 20, 2025 | Pimblett Emily | Executive Officer | Sell | 1,199 | $1.31 | $2K | SEC |
| Dec 20, 2024 | Pimblett Emily | Executive Officer | Sell | 1,235 | $2.02 | $2K | SEC |
In the last 12 months Climb Bio, Inc. insiders made open-market purchases worth about $780,000 and sales worth about $2.7 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CLYM was filed on 2026-09-17.
109 investment managers reported holding CLYM in SEC Form 13F filings for Q2 2026.
No congressional trades in CLYM were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).